Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: A multicentre, open-label, randomized trial

PLoS Neglected Tropical Diseases

Volumn 4, Issue 10, 2010, Pages

  Hailu, Asrat ^a   Musa, Ahmed ^b   Wasunna, Monique ^c   Balasegaram, Manica ^d,e   Yifru, Sisay ^f   Mengistu, Getahun ^b   Hurissa, Zewdu ^f   Hailu, Workagegnehu ^f   Weldegebreal, Teklu ^g   Tesfaye, Samson ^g   Makonnen, Eyasu ^a   Khalil, Eltahir ^b   Ahmed, Osama ^b   Fadlalla, Ahmed ^h   El Hassan, Ahmed ^b   Raheem, Muzamil ^b   Mueller, Marius ^d   Koummuki, Yousif ^d   Rashid, Juma ^c   Mbui, Jane ^c   Mucee, Geoffrey ^c   Njoroge, Simon ^c   Manduku, Veronica ^c   Musibi, Alice ^c   Mutuma, Geoffrey ^c   Kirui, Fredrick ^c   Lodenyo, Hudson ^c   Mutea, Dedan ^c   Kirigi, George ^c   Edwards, Tansy ⁱ   Smith, Peter ⁱ   Muthami, Lawrence ^c   Royce, Catherine ^e   Ellis, Sally ^e   Alobo, Moses ^e   Omollo, Raymond ^e   Kesusu, Josephine ^c   Owiti, Rhoda ^c   Kinuthia, John ^e   more..

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

^b UNIVERSITY OF KHARTOUM   (Sudan)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

^f UNIVERSITY OF GONDAR   (Ethiopia)

^g Arba Minch Hospital   (Ethiopia)

^h UNIVERSITY OF GADARIF   (Sudan)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; PAROMOMYCIN; STIBOGLUCONATE SODIUM; ANTIPROTOZOAL AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AFRICA; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ARTICLE; CHILD; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; GASTROENTERITIS; GEOGRAPHIC DISTRIBUTION; HEART FAILURE; HUMAN; HYPERAMYLASEMIA; INDIA; INFECTION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PANCREATITIS; PNEUMONIA; POST KALA AZAR DERMAL LEISHMANIASIS; POST KALA AZAR DERMAL LEISMANIASIS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SKIN LEISHMANIASIS; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VISCERAL LEISHMANIASIS; COMPARATIVE STUDY; GEOGRAPHY; ISOLATION AND PURIFICATION; LEISHMANIA DONOVANI; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AFRICA, EASTERN; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GEOGRAPHY; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; PAROMOMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78449231253     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000709     Document Type: Article

References (21)

1. Hailu A, Musa AM, Royce C, Wasunna M (2005) Visceral leishmaniasis: new health tools are needed. PLoS Med 2: e211.
2. World Health Organization (2007) Fifth Consultative Meeting on Leishmania/ HIV Coinfection, Addis Ababa, Ethiopia. Geneva, Switzerland: World Health Organization.
3. Desjeux P (1996) Leishmaniasis. Public health aspects and control. Clin Dermatol 14: 417-423.
4. Reithinger R, Brooker S, Kolaczinski JH (2007) Visceral leishmaniasis in Eastern Africa-current status. Trans R Soc Trop Med Hyg 101: 1169-1170.
5. Rijal S, Chappuis F, Singh R, Boelaert M, Loutan L, et al. (2003) Sodium stibogluconate cardiotoxicity and safety of generics. Trans R Soc Trop Med Hyg 97: 597598.
6. Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, et al. (1998) Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Ann Trop Med Parasitol 92: 561-569.
7. Anoopa Sharma D, Bern C, Varghese B, Chowdhury R, Haque R, et al. (2006) The economic impact of visceral leishmaniasis on households in Bangladesh. Trop Med Int Health 11: 757-764.
8. Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111-126.
9. Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, et al. (2006) A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 43: 357-364.
10. Schilling RT, Schaffner CP (1961) Differentiation of catenulin-neomycin antibiotics: identity of catenulin, paromomycin, hydroxymycin and aminocidin. Antimimicrob Agents Chemother 4.
11. Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, et al. (1998) Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 316: 1200-1205.
12. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Messick C, et al. (2000) Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 94: 432-433.
13. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Zaniewski AE, et al. (2000) A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 94: 429-431.
14. Chunge CN, Owate J, Pamba HO, Donno L (1990) Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 84: 221-225.
15. Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson AD, et al. (1993) Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 168: 715-720.
16. Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, et al. (2007) Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg 77: 89-94.
17. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK (2007) Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med 356: 2571-2581.
18. World Health Organization (2004) Guidelines on Hearing Aids and Services for Developing Countries. 2nd Edition. Available: http://whqlibdoc.who.int/publications/2004/9241592435_eng.pdf. Accessed 2010 Apr 14.
19. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, et al. (1998) Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76: 25-32.
20. Davidson RN, den Boer M, Ritmeijer K (2009) Paromomycin. Trans R Soc Trop Med Hyg 103: 653-660.
21. Ritmeijer K, Davidson RN (2003) Royal Society of Tropical Medicine and Hygiene joint meeting with Medecins Sans Frontieres at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. Medecins Sans Frontieres interventions against kala-azar in the Sudan, 1989-2003. Trans R Soc Trop Med Hyg 97: 609-613.